BioNTech SE stock dips as CEO share sales and trial update reshape risk view

Published on 09/20/2026 at 11:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BioNTech SE stock traded around USD 95.83 on Nasdaq as of September 18, 2026 after CEO Ugur Sahin sold tens of thousands of shares at prices near USD 98.60 and USD 96.22. Updated oncology trial data and a BMO Capital Markets downgrade to Market Perform frame the risk-reward for investors.

BioNTech SE, US09075V1026, Illustration mit AI erstellt.

BioNTech SE stock (ISIN US09075V1026) traded around USD 95.83 on Nasdaq as of September 18, 2026, reflecting a recent pullback that coincides with sizable share sales by CEO Ugur Sahin and mixed signals from the company’s vaccine and oncology pipeline.

CEO share sales and analyst stance

According to InsiderTrades on September 19, 2026, BioNTech CEO Ugur Sahin sold 30,000 BioNTech shares at an average price of USD 96.22 on September 18, 2026, generating proceeds of roughly USD 2.89 million and leaving him with 489,209 shares in the company.

Earlier transactions detailed by Ad-hoc-news citing StockTitan show Sahin executing Rule 10b5-1 plan sales totaling 64,000 ordinary shares on September 17 and September 18, 2026 at weighted-average prices of USD 98.60 and USD 96.22 per share, reinforcing a pattern of insider selling rather than a one-off event.

Based on data summarized by InsiderTrades, analysts currently assign BioNTech a consensus “Moderate Buy” rating with an average price target of USD 126.00, implying upside of around 31 percent compared with the roughly USD 96.00 level at which the shares recently traded.

Pipeline data and BMO Capital downgrade

As Ad-hoc-news reported on September 20, 2026, updated results from the Phase 3 PRESERVE-003 trial in squamous non-small cell lung cancer showed BioNTech’s partner OncoC4 antibody Gotistobart achieving a median overall survival of 18.5 months versus 10.0 months for standard chemotherapy docetaxel, based on a data cutoff of July 17, 2026 and a hazard ratio of 0.56.

Despite this oncology strength, the same report notes that U.S. regulators recently cleared BioNTech’s XFG-targeted vaccine, developed with Pfizer, for the upcoming immunization season, yet the stock’s reaction has been subdued amid ongoing concerns about softening global demand for COVID vaccines.

According to Ad-hoc-news, BMO Capital Markets downgraded BioNTech stock from Outperform to Market Perform on September 8, 2026 and cut its price target to USD 105 from USD 128, trimming the target by USD 23 and citing vaccine demand headwinds and inventory destocking in Germany as key risks.

Stock performance and valuation context

Per Nasdaq data relayed by Ad-hoc-news, BioNTech SE stock recently changed hands at USD 95.83 on Nasdaq at 11:37 a.m. Eastern Time on September 18, 2026, down USD 2.83 or about 2.87 percent compared with the prior close, within a trailing 52-week range between USD 68.35 and USD 105.80 and corresponding to a market capitalization close to USD 22.0 billion as of that date.

The same overview points out that BioNTech shares remain roughly 21 percent below their 52-week high, yet have delivered a modest 3.0 percent gain since the start of 2026, underscoring how investors are weighing near-term COVID-vaccine headwinds against the longer-term potential of the company’s oncology pipeline.

For investors, the juxtaposition of CEO share sales near the USD 96.00 to USD 98.60 range, the BMO Capital Markets target cut from USD 128 to USD 105, and consensus expectations around USD 126.00 highlights a valuation picture in which upside scenarios depend heavily on execution in late-stage oncology trials and the durability of booster-vaccine demand.

BioNTech SE stock price as of last trading day

On Nasdaq, BioNTech SE stock closed at USD 96.06 on September 18, 2026, with the session’s trading range between USD 95.71 and USD 99.25 and volume around 1.20 million shares, according to price history data for the BNTX ticker as of that date.